Andra AP fonden Purchases Shares of 4,622 Stryker Corporation $SYK

Andra AP fonden acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,622 shares of the medical technology company’s stock, valued at approximately $1,709,000.

Other large investors have also made changes to their positions in the company. Norges Bank bought a new position in Stryker during the 2nd quarter valued at about $1,882,173,000. Alliancebernstein L.P. increased its holdings in shares of Stryker by 307.6% during the second quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after buying an additional 4,223,366 shares in the last quarter. Corient Private Wealth LLC raised its stake in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. ABN AMRO Bank N.V. acquired a new position in shares of Stryker in the 2nd quarter worth approximately $191,047,000. Finally, Vanguard Group Inc. grew its position in Stryker by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after acquiring an additional 440,607 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on SYK. Needham & Company LLC lifted their price objective on Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Piper Sandler restated an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. Robert W. Baird set a $437.00 price target on shares of Stryker in a research report on Friday, January 30th. Wells Fargo & Company increased their price objective on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Finally, Barclays reaffirmed an “overweight” rating and issued a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. Thirteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $426.47.

Stryker Trading Up 0.3%

SYK opened at $387.34 on Monday. The firm has a 50 day simple moving average of $363.17 and a 200 day simple moving average of $369.09. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $404.87. The company has a market cap of $148.23 billion, a price-to-earnings ratio of 46.11, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21.

Stryker (NYSE:SYK) last released its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.01 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio is currently 41.90%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.